Secretome Therapeutics Secures $30 Million Series A Financing Led by RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics has announced the successful completion of a $30 million Series A financing round led exclusively by RA Capital Management,…
LINZESS® (linaclotide) Receives FDA Approval for Children Aged 2 and Older with Functional Constipation Ironwood Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an expanded indication for LINZESS, allowing the treatment to be used in pediatric…
Verastem Oncology Names Michael P. Bailey to Board of Directors Verastem Oncology has announced the appointment of veteran biotechnology executive Michael P. Bailey to its Board of Directors, strengthening the company’s leadership team as it advances a growing portfolio of…
Datroway Gains Landmark U.S. Approval for First-Line Treatment of Metastatic Triple-Negative Breast Cancer In a major advancement for breast cancer treatment, Daiichi Sankyo and AstraZeneca have announced that the U.S. Food and Drug Administration (FDA) has approved Datroway® (datopotamab deruxtecan-dlnk)…
Henry Schein Appoints Dan Daniel as Independent Chairman Following Stanley Bergman’s Retirement Henry Schein has announced a major leadership transition as its Board of Directors elected William K. “Dan” Daniel to serve as Independent Chairman of the Board, effective May…
Gilead Wins CHMP Backing for Trodelvy® in First-Line Metastatic TNBC Treatment Gilead Sciences has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of Trodelvy…
DiaMedica Therapeutics announced that it has reached approximately 75% enrollment in its ReMEDy2 Phase 2/3 acute ischemic stroke trial, marking a key development milestone in the study. DiaMedica Therapeutics Inc. announced a significant development in its late-stage clinical program for…
Texas Cancer Institute Implements Kallisio Technologies Stentra™ as Standard-of-Care for Precision Radiation Therapy After Successful Clinical Pilot Kallisio announced that the Texas Cancer Institute has officially transitioned its use of the company’s Stentra™ system from a pilot evaluation phase into…
Atrandi Biosciences Enhances Executive Team to Drive International Growth of Its Innovative Single-Cell Technology Atrandi Biosciences has expanded its executive and governance leadership team with the appointment of Sam Ropp as Chief Commercial Officer and Susan Tousi as Chairman of…
TRIANA Biomedicines Appoints Mohan Bala as COO and Expands Scientific Advisory Board With Industry Experts TRIANA Biomedicines has announced a series of major leadership and scientific advisory appointments as the company continues expanding its molecular glue degrader platform and advancing…
Endospan Completes Acquisition by Artivion, Inc. After FDA Approval of the NEXUS® Aortic Arch System Endospan has announced the completion of its acquisition by Artivion in a deal that significantly strengthens Artivion’s position in the global aortic repair market and…
BAXFENDY Becomes First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension in the U.S. AstraZeneca has announced that the U.S. Food and Drug Administration has approved BAXFENDY for the treatment of hypertension in adults whose blood pressure remains inadequately controlled…